Iovance Biotherapeutics, Inc. (0JDK.L)

12,16 -0,09 (-0,73%) Börsenschluss: 07:13PM BST

Iovance Biotherapeutics, Inc.

825 Industrial Road
Suite 400
San Carlos, CA 94070
United States
650 260 7120
https://www.iovance.com

Sektor(en): 
Branche: 
Vollzeitmitarbeiter: 557

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Frederick G. Vogt Esq., J.D., Ph.D.	Interim CEO, President, General Counsel & Corporate Secretary	1,39M	N/A	1974
Mr. Jean-Marc Bellemin M.B.A.	CFO, Principal Accounting Officer & Treasurer	932,2k	N/A	1973
Dr. Igor P. Bilinsky	Chief Operating Officer	932,2k	N/A	1973
Dr. Friedrich Graf Finckenstein M.D.	Chief Medical Officer	1,06M	N/A	1967
Ms. Sara Pellegrino	Vice President of Investor Relations & Public Relations	N/A	N/A	N/A
Ms. Tracy Winton	Senior Vice President of Human Resources	N/A	N/A	N/A
Mr. Howard B. Johnson M.B.A.	Chief Business Officer	N/A	N/A	1960
Mr. James Ziegler M.B.A.	Executive Vice President of Commercial	N/A	N/A	N/A
Dr. Raj K. Puri M.D., Ph.D.	Executive VP of Regulatory Strategy & Translational Medicine	N/A	N/A	N/A
Mr. Brian Shew M.B.A.	Senior VP & Head of Digital and Information Technology	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2022 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Corporate Governance

Iovance Biotherapeutics, Inc.s ISS Governance QualityScore, Stand 29. April 2024, lautet 5. Die grundlegenden Scores sind Audit: 7, Vorstand: 6, Shareholderrechte: 3, Kompensation: 7.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.